Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAmB-FAST: Liposomal Amphotericin B and Flucytosine for Talaromycosis
NCT06525389Phase 3Not yet recruiting
- Sponsor
- Duke University
- Start
- Nov 2026
- Primary completion
- Sep 2030
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of liposomal amphotericin b and flucytosine in talaromycosis (4 arms), sponsored by Duke University. Primary endpoint: Time from enrollment to a composite of poor outcomes at 24 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
liposomal amphotericin bflucytosine
03
Conditions
talaromycosis
Beyond the preview
Go deeper on NCT06525389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525389.